TheProfitWatch

IMMX - Immix Biopharma, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
2.45 0.12 (4.96%) --- --- --- 0.03 (1.22%) 0.14 (5.65%) 0.0 (0.05%) 0.0 (0.05%)

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Closed

Earnings & Ratios

Basic EPS:
-0.22
Diluted EPS:
-0.22
Basic P/E:
-11.6882
Diluted P/E:
-11.6882
RSI(14) 1m:
100.0
VWAP:
2.57
RVol:

Events

Period Kind Movement Occurred At

Related News